Feb XXVIII: The results of the trial demonstrated that a novel receptor chimeric antigen T-cell justo elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T.
According to statistics given during the Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, all but one of the 20 study patients who achieved an initial full response to therapy remained in remission as of the cutoff date.
"Nos numquam putavimus responsum rates altum hoc fore". Matthew Frank, MD, PhD, assistens professor medicinae in divisione sanguinis et medullae transplantationis et therapiae cellularum in Stanford University, dixit Healio. "Est valde efficax et incolume CAR-T aegris dare, qui magnam necessitatem habent."
Background
The CD22 protein on the surface of cancer cells is the scopum of an investigational autologous CAR T-cell treatment developed by Stanford University researchers. Using the CliniMACS Prodigy (Miltenyi Biotec) automated cell processing equipment, they produced the agent on-site over a 12-day period.
CD22 directa CAR-T consecuta est in 70% plenitudine responsionis inter 58 aegros iuniores relapso vel refractorio B-cellorum OMNES quorum infirmitas ante CD19 directa CAR-T sequentis progressus est.
Franke affirmavit "Dimidium aegris nostris adhuc relapsum esse cum utens commercii CAR-T, et communis causa recidivi erat ordinatio vel deletio CD19." Responsiones anticipavimus per antigenam diversam, quae pro iuvenibus promittens apparuit.
methodorum sive inventarum
Frank and coworkers tested their novel CD22-targeted Currus T-cell curatio in a phase 1, single-institution, dose-escalation study.
The trial enrolled 38 persons (median age, 65 years; age range, 25-84; 55% men) with relapsed or refractory large B-cell lymphoma whose disease progressed after prior CD19-directed CAR-T therapy or had CD19-negative disease.
Omnes aegroti praeter eum, qui in iudicio tractati sunt, antea CD19 directi sunt CAR T-cell Lorem. Participes lymphodepletionem subiverunt ante recipiendam unam infusionem cellularum CD22 CAR T sub dosis vel 1 106 cellularum / kg (n = 29) vel 3 106 cellularum / kg (n = 9).
The primary outcomes of this study were feasibility, safety, and the recommended phase 2 dose. Secondary objectives included overall response rate as determined by the investigator, duration of response, PFS, OS, and CAR-T-associated toxicity. At a cutoff date of December 27, 2022, the median follow-up period was 18.4 months (range: 1.5-38.6).
key Inventiones
36 people were diagnosed with cytokine release syndrome. The only grade 3 adverse event occurred in the group receiving the highest dose. In the higher-dose group, grade 2 CRS occurred significantly more frequently (78% vs. 48%).
Quinque aegros (13%) syndrome neurotoxicitatem cum effectore cellulis immunibus consociata habuerunt. In iudicio nullae causae graves ICANS (gradus 3 vel supra) nuntiabantur.
Five patients, including three of the nine who received the larger dose, were diagnosed with CAR-associated hemophagocytic lymphohistiocytosis (HLH), a hyperinflammatory response marked by significant hyperferritinemia and multiorgan failure.
The examination of efficacy revealed an ORR of 68% and a complete response rate of 53% for all patients treated. A complete response was achieved by fifteen patients (52%) who received the lower dose, and five individuals (56%) who received the larger dose.
Investigatores invenerunt medianum PFS 2.9 mensium (95% fiduciae intervallum [CI], 1.7 ad non perventum) et medianum OS 22.5 mensuum (95% CI, 8.3 usque ad non pervenerunt). In terminis medianis PFS (3 mensium vs. 2.6 mensium) et mediana OS, doses inferiores et superiores demonstrant efficaciam comparabilem (non attigit vs. 22.5 menses).
As of the study’s end date, only one of twenty patients who had complete remission reported an illness return.
Researchers picked 1 106 cells/kg as the phase 2 dose recommendation because of its superior safety profile and comparable efficacy compared to the larger dose.
effectus orci
Cum experimentum in anno 2018 incepit, parum intellectum est de quare quidam aegroti CAR-T relabantur. Frank affirmavit theoriam fundamentalem extra biologiam tumorem pauperem T-cellae congruentem fuisse.
Frank told Healio, “We’ve kind of blown that [thesis] out of the water because we’re taking the same autologous T cells from patients who have had a prior CAR-T and still getting a nearly 70% response rate and a 53% full response rate that appears to be quite durable.” This medication is quite promising, as it has a good response rate and a reasonable safety profile.
Proposita periodo 2 multicentri experimento utens CD22 CAR-T comprehendet aegros lymphoma magna B-cellorum qui sequentem curationem relapsi sunt cum CD19 directis CAR-T. Tempus dilectum verisimiliter hac aestate incipiet.
References:
- Frank MJ, et al. Abstract 2. Presented at: Tandem Meetings | ASTCT et CIBMTR, 15-19, 2023; Orlandus.
- Shah NN, et al. Clin J Oncol. 2020; doi: 10.1200/JCO.19.03279.
